<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744054</url>
  </required_header>
  <id_info>
    <org_study_id>201209062</org_study_id>
    <nct_id>NCT01744054</nct_id>
  </id_info>
  <brief_title>Microsphere Localization Using PET/MRI in Patients With Liver Disease</brief_title>
  <acronym>PET/MRI</acronym>
  <official_title>Pilot Study of Microsphere Localization Using PET/MRI in Patients With Liver Disease Following Radioembolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate y90-PET/MRI (Positron Emission Tomography / Magnetic Resonance Imaging) for its
      potential on reporting 1) technical success of radioembolization and 2) presence of
      extrahepatic deposition of microspheres
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Evaluate y90-PET/MRI for its potential on reporting presence of extrahepatic deposition of microspheres</measure>
    <time_frame>1 day (one time event for patient)</time_frame>
    <safety_issue>No</safety_issue>
    <description>An MR diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine any presence of extrahepatic deposition of microspheres.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate y90-PET/MRI for its potential on reporting technical success of radioembolization</measure>
    <time_frame>1 day (one time event for patient)</time_frame>
    <safety_issue>No</safety_issue>
    <description>An MR diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine whether technical success of the procedure can be determined. They will rate the images if they are 'adequate' to report on these two measures.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>PET/MR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients must have had radioembolization, within 72 hours of the PET/MR</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET/MR</intervention_name>
    <arm_group_label>PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must successfully complete the MRI screening form

          -  Participant must be scheduled to undergo radioembolization for liver disease

          -  Participant must be â‰¥ 18 years of age

          -  Participant must be able to understand and willing to sign an Institutional Review
             Board (IRB)-approved written informed consent document

        Exclusion Criteria:

          -  Participant must not have any contraindications to MRI scanning

          -  Patient must not be pregnant or breastfeeding

          -  If agreeing to MRI contrast, participant must not have renal insufficiency
             (glomerular filtration rate (GFR &lt; 30 mL/min/1.73 m2) measured within the past 60
             days

          -  If agreeing to MRI contrast, participant must not be on dialysis

          -  If agreeing to MRI contrast, participant must not have had a prior allergic reaction
             to gadolinium-based contrast agents

          -  PET/MRI is not able to be scheduled within 72 hours of radioembolization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parag Parikh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parag Parikh, M.D.</last_name>
    <phone>314-747-9614</phone>
    <email>pparikh@radonc.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parag Parikh, M.D.</last_name>
      <phone>314-747-9614</phone>
      <email>pparikh@radonc.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ananya Benegal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akash Sharma, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Olsen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Fowler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard LaForest, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Garcia-Ramirez, M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seth Klein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nael Saad, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darryl Zuckerman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd DeWees, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
